文献速递膀胱癌与上尿路尿路上皮癌

仅淋巴结转移性尿路上皮癌患者接受纳武利尤单抗联合GC方案对比GC方案的CheckMate 901试验分析

Characterization of Patients with Lymph Node Only Metastatic Urothelial Carcinoma Treated with Nivolumab Plus Gemcitabine-Cisplatin Versus Gemcitabine-Cisplatin Alone from the CheckMate 901 Trial.
PubMed 文献 · Eur Urol · 2025-05-20

CheckMate 901三期随机试验的事后探索性分析,在中位随访33.6个月时评估仅淋巴结转移的转移性尿路上皮癌患者(n=110),比较纳武利尤单抗联合吉西他滨-顺铂(NIVO+GC)与GC单独治疗的疗效。结果显示NIVO+GC组总生存(HR 0.58,95%CI 0.34-1.00)和无进展生存(HR 0.38,95%CI 0.22-0.66)均改善,客观缓解率81% vs 64%,完全缓解率63% vs 34%,安全性相似。

要点

  • 仅淋巴结转移亚组中NIVO+GC较GC改善OS(HR 0.58)和PFS(HR 0.38)。
  • NIVO+GC组ORR 81% vs 64%,完全缓解率63% vs 34%。
  • 两组治疗相关不良事件发生率相似。

核心结论

  • 在仅淋巴结转移的mUC患者中,NIVO+GC较GC在OS、PFS和ORR方面显示临床意义改善,完全缓解率翻倍,支持一线NIVO联合顺铂为基础化疗用于mUC。

研究设计与样本

  • CheckMate 901为三期随机试验(n=608),纳入顺铂合格的初治不可切除或转移性尿路上皮癌患者。
  • NIVO+GC组接受NIVO 360 mg联合GC每3周一次,最多6周期,随后NIVO 480 mg每4周一次,最长2年;GC组接受GC每3周一次,最多6周期。
  • 本次为事后探索性分析,评估仅淋巴结转移mUC患者(n=110),中位随访33.6个月。
  • 主要终点为盲法独立中心评审(BICR)评估的OS和PFS;ORR(BICR)和安全性为探索性终点。

主要发现

  • 仅淋巴结转移亚组中,NIVO+GC较GC改善OS(HR 0.58;95%CI 0.34-1.00)。
  • 仅淋巴结转移亚组中,NIVO+GC较GC改善PFS(HR 0.38;95%CI 0.22-0.66)。
  • NIVO+GC组ORR为81%,GC组为64%;完全缓解率分别为63%和34%。
  • 两组治疗相关不良事件发生率相似。

临床怎么用

  • 对于仅淋巴结转移的转移性尿路上皮癌且顺铂合格患者,可考虑一线NIVO联合GC方案。
  • 该亚组分析支持NIVO+GC在仅淋巴结转移患者中带来更高的完全缓解率和更多无治疗间隔。

局限性

  • 该分析为事后探索性分析,仅淋巴结转移亚组样本量有限(n=110)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Nivolumab (NIVO) plus gemcitabine-cisplatin (GC) demonstrated deep, durable responses in patients with untreated unresectable or metastatic urothelial carcinoma (mUC) with superior overall (OS) and progression-free (PFS) survival versus GC alone. We report post hoc exploratory analyses with 33.6 mo of median follow-up in patients with lymph node (LN) only disease from CheckMate 901. In this phase 3 randomized trial (n = 608), cisplatin-eligible patients received NIVO 360 mg plus GC every 3 wk (Q3W) for six or fewer cycles followed by NIVO 480 mg every 4 wk for ≤2 yr, or GC Q3W for six or fewer cycles. The primary endpoints were OS and PFS by a blinded independent central review (BICR). The objective response rate (ORR) as per the BICR and safety were exploratory. This post hoc analysis evaluated patients with LN only mUC (n = 110). In this subgroup, OS (hazard ratio [HR], 0.58; 95% confidence interval [CI] 0.34-1.00) and PFS (HR, 0.38; 95% CI 0.22-0.66) improved with NIVO + GC versus GC. The ORR was 81% with NIVO + GC versus 64% with GC; complete response rates were 63% versus 34%. The incidence of treatment-related adverse events was similar between arms. In conclusion, clinically meaningful improvements in OS, PFS, and ORR, including twice the rate of complete response and more patients with treatment-free intervals, were observed with NIVO + GC versus GC in patients with LN only disease, providing additional support for first-line NIVO plus cisplatin-based chemotherapy in mUC.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Galsky MD, van der Heijden MS, Powles T, et al. Characterization of Patients with Lymph Node Only Metastatic Urothelial Carcinoma Treated with Nivolumab Plus Gemcitabine-Cisplatin Versus Gemcitabine-Cisplatin Alone from the CheckMate 901 Trial. Eur Urol. 2025. PMID: 40393861. doi:10.1016/j.eururo.2025.04.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。